Epigen Biosciences Licenses its LPA1 Receptor small molecule program to Novo Nordisk

Torreya advised Epigen on the license of its LPA1 receptor antagonist

San Diego, CA USA and Bagsværd, Denmark, May 23, 2018

Epigen Biosciences, a San Diego based biotechnology company focused on discovering therapies for unmet medical needs, announced it entered into a worldwide collaboration agreement to license its LPA1 receptor small molecule program including EPGN696 to Novo Nordisk for up to $200 million.

EPGN696 is an orally available, selective LPA1 receptor antagonist for development in diabetic and chronic kidney disease, and other chronic diseases associated with metabolic syndrome. In preclinical testing EPGN696 demonstrated efficacy and safety in rodent models of kidney disease by targeting fibrosis, inflammation and growth factor responses.

Torreya served as financial advisor to Epigen on this transaction. This transaction reinforces Torreya’s strength and leadership position as an advisor to biotechnology companies. Torreya has advised on 36 strategic and financing transactions in the life sciences industry in the last 18 months.

ABOUT EPIGEN BIOSCIENCES, INC
For more information about Epigen, please see: www.epigenbiosciences.com

ABOUT NOVO NORDISK A/S:
For more information about Novo Nordisk, please see: www.novonordisk.com

Deal Press Release

Torreya Contact

CHRISTINE FISCHETTE, PH.D.

Executive Director | New York Office
christine.fischette@torreyapartners.com | 973.978.0671 | torreya.com